进展性胃肠胰神经内分泌肿瘤重复[177Lu]Lu-DOTA-奥曲肽放射性核素治疗的安全性与疗效:单中心经验
回顾性分析63例进展性转移性胃肠胰神经内分泌肿瘤患者接受重复肽受体放射性核素治疗(R-PRRT)的安全性与疗效,多数为G2级和小肠原发;R1-PRRT后肾小球滤过率稳定,R2-PRRT后10%(2/20)患者肾小球滤过率从CTCAE G2恶化至G3,R1-PRRT后RECIST 1.1缓解CR 0%、PR 10%、SD 76%,GaTate PET/CT疾病控制率52/58(89%),中位无进展生存期1.6年(95%CI 1.2-2.3)。
要点
- R1-PRRT后肾小球滤过率稳定,R2-PRRT后10%(2/20)患者肾小球滤过率从CTCAE G2恶化至G3。
- R1-PRRT后RECIST 1.1缓解CR 0%、PR 10%、SD 76%,GaTate PET/CT疾病控制率52/58(89%)。
- R1-PRRT后中位无进展生存期1.6年(95%CI 1.2-2.3)。
核心结论
- R-PRRT对进展性胃肠胰神经内分泌肿瘤患者可行、可耐受且有效实现疾病控制。
研究设计与样本
- 回顾性分析,经机构伦理委员会批准,纳入因症状性或影像学进展而接受R-PRRT的胃肠胰神经内分泌肿瘤患者。
主要发现
- 共63例患者接受R1-PRRT(1-3周期),70%为G2级NET,51%为小肠原发。
- 20例接受第二次重复治疗(R2-PRRT),6例接受第三次(R3-PRRT)。
- R1-PRRT后肾小球滤过率稳定;R2-PRRT后10%(2/20)患者肾小球滤过率从CTCAE G2恶化至G3,R3-PRRT后无恶化。
- R1-PRRT后2例发生G3级血小板减少,1例发生G4级血小板减少;R3-PRRT后1例发生G3级血小板减少。
- R1-PRRT后RECIST 1.1缓解CR 0%、PR 10%、SD 76%;GaTate PET/CT疾病控制率52/58(89%);中位无进展生存期1.6年(95%CI 1.2-2.3)。
关键数值与推荐
- 安全性采用CTCAE v5.0评估R-PRRT后3个月肾脏和血液学参数。
- 分子影像反应采用预先定义标准在[68Ga]Ga-DOTA-奥曲肽PET/CT上评估。
- R-PRRT后3个月在可行时记录RECIST 1.1缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Patients with gastro-entero-pancreatic neuroendocrine tumours (GEP NET) who retain somatostatin receptor (SSTR) expression after initial response to [177Lu]Lu-DOTA-Octreotate (LuTate) peptide receptor radionuclide therapy (PRRT) are amenable to re-treatment (R-PRRT) upon progression. We assessed the safety and efficacy of R-PRRT in patients with progressive metastatic GEP NET. MATERIALS AND METHODS: A retrospective analysis, approved by institutional ethics board, was performed in patients with GEP NET who received R-PRRT for either symptomatically or radiologically progressive disease. Safety was assessed by renal and haematological parameters at 3 months post R-PRRT (CTCAE v5.0). Molecular imaging response was evaluated on [68Ga]Ga-DOTA-Octreotate (GaTate) PET/CT using pre-defined criteria. RECIST 1.1 responses 3 months post R-PRRT were documented when feasible. Progression-free and overall survival analysis were performed. RESULTS: A total of 63 patients had R1-PRRT (1-3 cycles). The majority (70%) had Grade 2 NET and small intestinal primary (51%). A second re-treatment course (R2-PRRT) was given in 20 patients and a third course (R3-PRRT) in 6 patients. Glomerular filtration rate (GFR) was stable following R1-PRRT. Following R2-PRRT, worsening GFR from CTCAE G2 to G3 was seen in 10% (2/20) of patients, but none after R3-PRRT. Grade 3 thrombocytopenia occurred in 2 patients after R1-PRRT and in 1 patient after R3-PRRT. Grade 4 thrombocytopenia was observed in 1 patient post R1-PRRT. Following R1-PRRT, RECIST 1.1 responses CR, PR, SD was 0%, 10%, 76%, respectively. Disease control rate on GaTate PET/CT was 52/58 (89%) post R1-PRRT. Median progression free survival (PFS) following R1-PRRT was 1.6 years (95% CI:1.2-2.3). CONCLUSION: R-PRRT is feasible, tolerable and efficacious in achieving disease control in patients with progressive GEP NET.
引用
- Kashyap R, Alipour R, Boehm E, et al. Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience. Eur J Nucl Med Mol Imaging. 2025. PMID: 40137978. doi:10.1007/s00259-025-07235-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。